Incidence and outcome of CMV and EBV reactivations after autologous HSCT for autoimmune diseases: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type:

Retrospective Studies

Study number:

8410033

Type of treatment:

Diseases:

Auto immune disorders

Short title:

CMV EBV reactivation

Primary objective:

To identify the cumulative incidence, risk factors and outcome of CMV/EBV viraemia (ie, virus detection without clinical symptoms), CMV/EBV disease (ie, detection of viraemia and clinically relevant end organ disease) and CMV/EBV clinically significant infection (CMV/EBV viraemia leading to pre-emptive treatment) in patients who received autologous HSCT for an autoimmune disease (AD) at 100 days and 1 year following auto-HSCT. To assess centre practice in screening and treatment of CMV and EBV in the context of auto-HSCT for AD.

Key inclusion criteria:

All patients registered in the EBMT database receiving a first autologous HSCT for AD between 2009 and 2019

Country:

Principal investigator:

Tobias Alexander

EBMT Study coordinator:

Manuela Badoglio

Study coordinator email:

manuela.badoglio@upmc.fr